A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-Cell Malignancies.

Trial Profile

A Phase I, Open Label, Dose Ascending Study of BCX1777 (Oral) in Patients With Recurrent or Refractory T/NK-Cell Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Forodesine (Primary)
  • Indications Lymphoma
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Mundipharma International
  • Most Recent Events

    • 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jan 2013 Planned number of patients changed from 10 to 24 as reported by ClinicalTrials.gov.
    • 15 Jan 2013 Planned End Date changed from 1 Aug 2010 to 1 Dec 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top